Sarepta Therapeutics Inc (SRPT)
114.23
+3.73
(+3.38%)
USD |
NASDAQ |
Nov 22, 16:00
114.23
0.00 (0.00%)
After-Hours: 20:00
Sarepta Therapeutics Revenue (TTM): 1.640B for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 1.640B |
| June 30, 2024 | 1.505B |
| March 31, 2024 | 1.403B |
| December 31, 2023 | 1.243B |
| September 30, 2023 | 1.105B |
| June 30, 2023 | 1.003B |
| March 31, 2023 | 975.68M |
| December 31, 2022 | 933.01M |
| September 30, 2022 | 876.05M |
| June 30, 2022 | 835.18M |
| March 31, 2022 | 765.79M |
| December 31, 2021 | 701.89M |
| September 30, 2021 | 645.56M |
| June 30, 2021 | 600.08M |
| March 31, 2021 | 573.36M |
| December 31, 2020 | 540.10M |
| September 30, 2020 | 495.07M |
| June 30, 2020 | 450.19M |
| March 31, 2020 | 407.50M |
| December 31, 2019 | 380.83M |
| September 30, 2019 | 365.14M |
| June 30, 2019 | 344.58M |
| March 31, 2019 | 323.44M |
| December 31, 2018 | 301.03M |
| September 30, 2018 | 273.90M |
| Date | Value |
|---|---|
| June 30, 2018 | 241.36M |
| March 31, 2018 | 202.85M |
| December 31, 2017 | 154.58M |
| September 30, 2017 | 102.73M |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | 9.757M |
| September 30, 2014 | 12.36M |
| June 30, 2014 | 15.46M |
| March 31, 2014 | 15.83M |
| December 31, 2013 | 14.22M |
| September 30, 2013 | 18.93M |
| June 30, 2013 | 22.34M |
| March 31, 2013 | 30.59M |
| December 31, 2012 | 37.33M |
| September 30, 2012 | 43.58M |
| June 30, 2012 | 43.53M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
380.83M
Minimum
Dec 2019
1.640B
Maximum
Sep 2024
854.03M
Average
800.48M
Median
Revenue (TTM) Benchmarks
| Eli Lilly and Co | 40.86B |
| Catalyst Pharmaceuticals Inc | 460.48M |
| Regeneron Pharmaceuticals Inc | 13.85B |
| Vertex Pharmaceuticals Inc | 10.63B |
| Viking Therapeutics Inc | -- |